The preferred first-line therapy for glaucoma, SLT. Designed specifically for selective laser trabeculoplasty (SLT), Solo allows you to perform quick and highly accurate glaucoma laser treatment customized to each individual patient’s response. LiGHT Trial1 confirms SLT as preferred first-line therapy for glaucoma he pivotal results of the multi-center LiGHT trial compared T the use of SLT versus drops as a first-line treatment for treatment-naive patients who had POAG or OHT over 36 months. SLT (329 patients) Eye drops (323 patients) 74.2% of SLT patients reached target IOP, drop-free 1 Selective laser trabeculoplasty versus eye drops for first-line treatment of ocular hypertension and glaucoma (LiGHT): a multicentre randomised controlled trial. Gus Gazzard, Evgenia Konstantakopoulou, David Garway-Heath, et al.; on behalf of the LiGHT Trial Study Group. Glaucoma treatment

TECHNICAL SPECIFICATIONS Laser Source Q-switched, frequency doubled Nd:YAG 0.3 to 2.6 mJ, single pulse, continuously variable Pulse Width Spot Size Repetition Rate Sharp edged SLT aiming beam for critical focus Aiming Beam Comprehensive energy tracking system, regulating settings for extended duration Dimensions (HxWxD) Custom-designed optics that provide an enhanced view of the trabecular meshwork LED illumination for superior visualization and greater patient benefits Ultra-stable laser energy output Evaluate pathology If SLT is effective, primary obstruction may reside within the trabecular...